Philip Astley-Sparke

Executive Chairman & Co-founder, Replimune
· tracked since Apr 2026
Calls
1
Win Rate
100.0%
return
+518.2%
Calls 1 1 Posts tracked · 0.0/day
Calls
7d 0
30d 0
90d 0
Best Calls
REPL Long +518.2%
Worst Calls
No live losers yet
Most Mentioned
REPL ×1
Recent Calls
REPL Long 3 months ago
Win Rate 100% Long 1 Short 0
Win Rate
7d 100%
30d 100%
90d 100%
Average Return +518.2% Long Return +518.2% Short Return -
Average Return
7d +21.8%
30d +211.8%
90d +484.4%
Loading charts...
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
REPL Replimun... Replimune Group, Inc.
Long
Apr 13
$1.70
+518.2%
Replimune's drug has strong efficacy and support.
The FDA rejection of Replimune's melanoma drug was unfair because the drug has strong efficacy data with a 34% remission rate and durable responses, it resensitizes patients to anti-PD-1 therapy, and has broad support from oncologists and patient advocacy groups, indicating that the drug should be approved and the company has promising prospects.
Pharma & Biotech
YOUTUBE
Showing 1 of 1 calls · sorted by mentions

Philip Astley-Sparke has 1 trade ideas tracked on Buzzberg across 1 tickers since April 2026. Most covered: REPL.